Last updated on November 2019

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

Clinical Study Identifier: NCT03518086

Find a site near you

Start Over

CHU Lille - H pital Claude Huriez

Lille cedex, France
3.84miles
  Connect »